aTyr Pharma (LIFE) – Globe Newswire
-
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
-
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
-
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
-
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
-
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
-
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
-
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
-
aTyr Pharma to Present at November Investor Conferences
-
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
-
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
-
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
-
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis
-
aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
-
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)
-
aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference
-
aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference
-
aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference
-
aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update
-
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
-
aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases
-
aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution
-
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
-
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
-
aTyr Pharma to Present at March Investor Conferences
-
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results
-
aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application
-
aTyr Pharma Announces Pricing of Public Offering of Common Stock
-
aTyr Pharma Announces Commencement of Public Offering of Common Stock
-
aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.
-
aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference
-
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
-
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
-
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
-
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
-
aTyr Pharma to Present at Upcoming Investor Conferences
-
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
-
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
-
aTyr Pharma to Present at the Jefferies London Healthcare Conference
-
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
-
aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
-
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
-
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
-
Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing
-
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
-
Life Sciences Virtual Investor Conference Agenda Announced for September 15th
-
aTyr Pharma to Present at the Life Sciences Investor Forum on September 15th
-
aTyr Pharma to Present at the Life Sciences Investor Forum on September 15th
Back to LIFE Stock Lookup